Latest From PharmAbcine Inc.
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
PharmAbcine CEO Jin-San Yoo talks to Scrip about the company’s overseas clinical trial strategy, pipeline assets, and ambitions for lead candidate TTAC-0001, which the company sees as superior to Avastin. The Korean biotech, which is engaged in various global collaborations on its investigative antibody drugs, hopes that tie-ups can lead to bigger outcomes going forward.
Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.
South Korea’s ABL Bio is tackling cancer and neurodegenerative diseases with its broad bispecific antibody pipeline and CEO Sang Hoon Lee outlines the firm’s multi-collaboration and licensing strategy.
- Large Molecule
- Therapeutic Areas
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- PharmAbcine Inc.
- Senior Management
- Jin-San Yoo, PhD, Pres. & CEO
- Contact Info
Phone: (82) 42 863 2017 9
461-8, Daejeon BioventureTown
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.